Compare Inovio Pharmaceuticals Inc (INO) vs Veritone Inc (VERI) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

VERI trades at $1.05, up 2.94% on the day, but remains in a bearish technical trend. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, while revenue declined to $92.19 million. Multiple securities class action lawsuits, with a July 20, 2026 deadline, highlight significant legal and reputational risks stemming from alleged improper revenue accounting.

The outlook is highly speculative given severe profitability challenges and ongoing litigation. Analyst consensus is split between Buy and Hold, but fundamental weaknesses and legal overhangs present substantial downside risk. Investment suitability is limited to risk-tolerant investors monitoring resolution of legal issues and a path to profitability.